FUJIFILM Holdings Corp · TSE:4901
FUJIFILM — Merger or Acquisition (December 2016)
13 slides from FUJIFILM's merger presentation, Dec 16, 2016
Slide 1: The Acquisition of Wako Pure Chemical Industries, Ltd.
The Acquisition of Wako Pure Chemical Industries, Industries Ltd Ltd. FUJIFILM Holdings Corporation President and Chief Operating p g Officer Kenji Sukeno December 16,, 2016
Slide 2: Overview of Acquisition
Overview of Acquisition Acquisition q Structure: Tender Offer of Wako Pure Chemical Industries,, Ltd. by FUJIFILM Tender Offer Price: JPY 8,535 per share Total Funds Necessary for Tender Offer: Approximately JPY154.7 billion (expected) E Expected t d Schedule： S h d l 2/27 - 4/3 Tender offer period
Slide 3: Overview of Wako Pure Chemical Industries, Ltd.
Overview of Wako Pure Chemical Industries, Ltd. Company Name： Wako Pure Chemical Industries, Ltd. Incorporation： 1922 Chemicals Department of Takeda Pharmaceutical separated and established Takeda Pure Chemicals Ltd Ltd. as an independent company Business Overview： Manufacturing g and sales of labor
Slide 4: Business Overview of Wako Pure Chemical (FY2016/3 Consolidated Basis)
Business Overview of Wako Pure Chemical (FY2016/3 Consolidated Basis) Laboratory Chemicals Revenue: JPY36.6bn (46％ of total) 9 Cell culture medium related 9 DNA/Protein research related 9 Analysis of environment/food area related 9 Organic synthesis related related, etc etc. Clinical Diagnostics Rea
Slide 5: Rationale and Objectives of Acquisition
Rationale and Objectives of Acquisition Three Fields to Drive Growth Highly Healthcare Document Functional Material Laboratory Chemicals Clinical Speciality Diagnostic Chemicals Reagents Combination of Respective Technologies to Realize Substantial Synergies 4
Slide 6: The Three Key Components for Regenerative Medicine
The Three Key Components for Regenerative Medicine Cell Scaffold (recombinant peptide) Cell Culture Medium/ C t ki Cytokine I House In H O Ownership hi off 3 K Key C Components t for Regenerative Medicine 5
Slide 7: Regenerative Medicine Business Synergy
Regenerative Medicine Business Synergy Cell Culture GMP Standard St d d Scaffold Medium Cell Production/ Manufacturing Manufacturing (recombinant peptide) Technology Facilities Cultivation Patent & Know-how Know how 画像診断 技術 Dispersion/Synthesis Technology Development/ Manufacturing of iPS Cell Devel
Slide 8: In-Vitro Diagnosis Synergy (Medical System Business)
In-Vitro Diagnosis Synergy (Medical System Business) ＜和光純薬＞Biochemical Immune Analysis Analysis Clinical Chemical Immunodiagnosis 免疫分析装置 System Laboratory Analysis System System 生化学分析試薬 Chemicals 国内の営業網 Extensive Sales Network Established International Network through Sales of Medical Device with Ac
Slide 9: Pharmaceutical CDMO Synergy (Pharmaceutical Business)
Pharmaceutical CDMO Synergy (Pharmaceutical Business) Chemical Synthesis Biologics Bi l i P Product d t ＜和光純薬＞ Technology of Small Chemical Cell Culture Medium Molecule Drugs Manufacturing Technology 免疫分析装置 Synthesis Manufacturing Technology Technology 生化学分析試薬 Biologics Product 国内の営業網 CDMO Vast Clie
Slide 10: Highly Functional Materials Synergy (Electronic Materials Business)
Highly Functional Materials Synergy (Electronic Materials Business) ＜和光純薬＞ Photoresist CMP Slurry 免疫分析装置 High Purity Cleaning Agent High Quality Etching Solution 生化学分析試薬 化学分析試薬 国内の営業網 Materials for Image Sensor, etc. Non-Ionic Surfactants, etc. Load CMP Slurry Wafer (face down) Polishing Pad Rotatin
Slide 11: Highly Functional Materials Synergy (Industrial Products Business)
Highly Functional Materials Synergy (Industrial Products Business) ＜和光純薬＞ ＜和光純薬＞ Chemical Ch i l 重合開始剤等 Synthesis 免疫分析装置 Polymerization 生化学分析試薬 Vast Polymeric Technology Chemical library Initiator Material with 200,000 kinds 国内の営業網 Analytic Technology Domestic and Global Speciality Chemical Strong G
Slide 12: Sales Target After Acquisition: JPY 100bn in Revenue by FY2022/3
Sales Target of Wako Pure Chemical After Acquisition To Achieve JPY 100bn in Revenue by FY2022/3 Further Growth 100 (JPY bn) 78 79 75 17 17 Speciality 16 Chemicals 50 Clinical 25 26 24 Diagnostics Reagents 35 36 37 Laboratory Chemicals 0 FY2014/3 FY2015/3 FY2016/3 FY2017/3 FY2018/3 FY2019/3 FY2020/3
Slide 13: FUJIFILM Value from Innovation
FUJIFILM Value from Innovation
FUJIFILM Holdings — Merger or Acquisition (December 2016) on 6ix